Galapagos' experimental bowel disease drug GLPG1205 failed to perform better than the placebo drug used in the medical trial. The Belgian pharmaceutical company is discontinuing the drug program for the treatment of ulcerative colitis.
Galapagos' experimental bowel disease drug GLPG1205 failed to perform better than the placebo drug used in the medical trial. The Belgian pharmaceutical company is discontinuing the drug program for the treatment of ulcerative colitis.
Share this Article
Recommended